Reviewer’s report

Title: Uric acid induces kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation

Version: 0 Date: 03 May 2017

Reviewer: Michiko Shimada

Reviewer's report:

The authors showed that hyperuricemia induced glomeruloclerosis, tubular injury and renal fibrosis in mice, and allopurinol ameliorated these changes. The methods and results were clearly demonstrated.

It is interesting that hyperuricemia induced podocyte damage demonstrated by reduced expression levels of podocin and nephrin and allopurinol ameliorated these changes. It would be reassuring if the levels of albuminuria were quantified.

The authors used daily intraperitoneal injection of uric acid, however, I am concerned about the daily variation of the uric acid concentration. Is there any data for the trough value of uric acid in this model? Is there any reason that you did not use uricase inhibitor?

The role of uric acid as a cause of renal damage is under an active debate, and there are many previous reports. Please clearly and separately state the novel data and the data you confirmed in this model.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal